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Introduction
Ankylosing spondylitis (AS) is a chronic debilitating inflammatory autoimmune disease characterized by arthritis and tendinitis of the spine and peripheral joints. Patients with AS have increased mortality compared to the general population, despite improved management and prognoses in recent decades. 1 Cardiovascular disease (CVD) has been confirmed as a crucial cause of mortality in AS patients. 2 Rapidly accumulating evidence now verifies that there is a higher prevalence of cardiac pathology (ie, myocardial disease, valvular heart disease) and atherosclerosis in patients with AS. [3] [4] [5] Of note, studies have shown that AS-related systemic inflammation plays a vital role in the pathogenesis of CVD. [6] [7] [8] CVD risk factors such as obesity, insulin resistance, lipid disorders, and hypertension constitute a pathophysiological condition called metabolic syndrome (MetS). It is acknowledged that MetS increases the risk of CVD and associated mortality. 9 Several studies have documented a higher prevalence of MetS in AS patients than in healthy subjects, [10] [11] [12] [13] but the factors leading to that finding are unknown. Given that few relevant studies of this problem have been done on the Chinese mainland, the present investigation was conducted to determine the prevalence of MetS in our Chinese AS patients living in the mainland and the possible determinants of its presence.
Patients and methods

Patients and controls
In this cross-sectional study, 117 AS patients who visited the Department of Rheumatology and Immunology at Guangdong Second Provincial General Hospital, Guangdong, China, from March 2016 and August 2018 were enrolled. The 117 consecutive patients met the modified New York criteria for the classification of AS, 14 but were excluded if they were ≤16 years of age or had a history of acute myocardial infarction, stroke, coronary artery bypass, peripheral artery occlusive disease, transient ischemic attacks, or chronic kidney disease. The control group included 117 ageand gender-matched healthy subjects who were selected randomly from the Department of Physical Examination Center of Guangdong Second Provincial General Hospital in 2018.They had no specific chief complaints and no history of CVD. The study was approved by the research ethics committee of Guangdong Second Provincial General Hospital (2018-FSKWZ-010), and all participants gave their informed written consent. Moreover, this study was conducted in accordance with the Declaration of Helsinki.
Classification of MetS
The criteria for MetS used in this study were those recommended by the Chinese Diabetes Society (CDS) in 2013, 15 which were modified so as to be more appropriate for the Chinese population. MetS was defined when three or more of the following criteria were met: abdominal obesity (waist circumference (WC) ≥90 cm in men and ≥85 cm in women), fasting blood glucose (FBG) ≥6.1 mmol/L or on drug treatment for elevated glucose, elevated blood pressure (≥130/85 mmHg or on drug treatment for hypertension), fasting blood triglycerides (TG) ≥1.7 mmol/L, and fasting blood high-density lipoprotein cholesterol (HDL-c) <1.04 mmol/L. 
Clinical evaluation and laboratory tests
Results
Comparisons between AS patients and controls
The comparisons of demographic characteristics, blood pressure, and laboratory measurements between AS patients and controls are listed in Table 1 . These two groups were similar with regard to age, gender, BMI, overweight/obesity, LDL-c, and SUA. The AS group showed higher systolic blood pressure (119.9 ± 11.5 vs 113.2 ± 12 mmHg; P <0.001), diastolic blood pressure (74.6 ± 7.9 vs 71.2 ± 9.9 mmHg; P <0.001), TC/HDL-c (3.9 ± 0.8 vs 3.5 ± 0.5; P <0.001), and FBG (5.0 ± 1.0 vs 4.9 ± 1.6 mmol/L; P= 0.004) and lower TC (4.2 ± 0.9 vs 4.8 ± 0.9 mmol/L; P <0.001), HDL-c (1.1 ± 0.2 vs 1.4 ± 0.3 mmol/L; P <0.001) and TG (1.2 ± 0.9 vs 1.7 ± 2.3 mmol/L; P <0.001) than controls. Finally, the AS patients had a higher prevalence of MetS than controls (19.7% vs 9.4%; P= 0.026) using the 2013 CDS criteria. Table 2 summarizes the characteristics of the MetS in AS patients and the controls. TC (4.6 ± 0.9 vs 5.3±1.6 mmol/ L; P =0.032) and HDL-c (1.4 ± 0.1 vs 1.6 ± 0.7 mmol/L; P =0.002) were lower in AS MetS patients relative to the controls while the ratio of TC/HDL-c (4.4 ± 0.9 vs 3.7 ± 0.6; P =0.018) was higher in AS MetS patients compared to the controls. No significant differences were found in age, sex, BMI, obesity, WC, blood pressure, FBG, LDL-c, TG, or SUA between the MetS in AS patients and the controls.
Comparison of all MetS subjects
Comparisons between the AS patients with and without MetS Abbreviations: TC, total cholesterol; HDL-c, high-density lipoprotein; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; HLA-B27, human leukocyte antigen-B27; BASDAI, Bath Ankylosing Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; TNF-i, tumor necrosis factor inhibitors; DMARDs, diseasemodifying anti-rheumatic drugs; NSAIDs, non-steroidal anti-inflammatory drugs.
observed in age, gender, smoking, drinking, disease duration, LDL-c, HDL-c, SUA, CRP, ESR, the positivity of HLA-B27, and BASDAI. Furthermore, the prescription rates for tumor necrosis factor inhibitors (TNF-i), diseasemodifying anti-rheumatic drugs, non-steroidal antiinflammatory drugs, and prednisone were also similar in the two groups. Table 4 summarizes the results of the logistic regression analyses. As there were only 0 or 1 patient with histories of smoking, drinking, or prednisone treatment in the MetS-AS group, apart from the components of MetS, those three variables were eliminated from the univariate analyses to avoid selection bias. In the univariate analyses, age, BMI, the ratio of TC/HDL-c, SUA, disease duration, and NSAID usage were identified as being different between the MetS AS patients and the non-MetS AS patients with P≤ 0.1, and therefore these variables were included in the multivariate regression analysis. Finally, two important predictors of MetS in AS patients were verified: SUA (OR = 2.385; 95% CI = 1.019-5.582; P =0.045) and high BMI (OR = 5.165; 95% CI = 1.935-13.787; P =0.001) ( Table 4) .
Associated factors of MetS in AS
Discussion
The present study confirmed that mainland Chinese AS patients had a higher prevalence of MetS than the general population. Furthermore, we verified that SUA and high BMI were independent predictors of MetS in these Chinese AS patients. According to the 2013 CDS criteria, this study found that MetS occurred in 19.7% of the AS patients as compared with 9.4% of the healthy individuals. Previous studies also investigated the prevalence of MetS in AS patients and found rates of 45.8% in Italy, 10 34.9% in Greece, 11 and 27% in Brazil. 13 Our study found a lower prevalence of MetS in Chinese AS patients than that indicated in foreign reports. This difference may result from the younger age of the AS patients in our study (35 vs 40-50.5 years) or the different criteria of MetS since the 2013 CDS criteria were developed to specifically define MetS for the Chinese. Different therapeutic strategies, genetic factors, and races should also be considered. However, the results of our study indicating that MetS was more prevalent in AS patients than in the controls was in agreement with previous studies. [10] [11] [12] [13] AS patients in this study had lower HDL-c and TC levels but higher TC/HDL-c ratios than the controls. AS patients with MetS also had lower HDL-c and TC but higher TC/ HDL-c ratios than the healthy controls with MetS. HDL-c has anti-inflammatory and anti-atherosclerotic properties. 20 Mathieu et al reported that decreased TC and HDL-c occurred in AS patients and that the low HDL-c levels appeared to play a crucial role in developing myocardial infarctions in AS patients. 21 Moreover, Toms et al found that TC/HDL-c had a better association with inflammatory biomarkers and CVD risk than TC or HDL-c in patients with rheumatoid arthritis. 22 Therefore, we further tested whether TC/HDL-c was an independent predictor of MetS in AS patients. In the univariate regression analyses, TC/HDL-c significantly increased the danger of MetS in AS patients (OR = 2.400; 95% CI = 1.348-4.274; P= 0.003). However, this ratio was removed from the analysis after adjustment with other factors. As an index for predicting the cardiac risk, TC/HDL-c in AS patients with MetS has an uncertain role and will need further investigation to establish its usefulness. In this study, SUA levels showed no difference between MetS and non-MetS in AS patients, which was in keeping with the results of Maia et al 13 .
Nevertheless, SUA was associated with AS MetS patients under the univariate regression analyses (P≤ 0.1). The cut point of SUA in the further multivariate regression analysis was 416.4 μmol/L for men and 356.9 μmol/L for women, which means that hyperuricemia independently increased the risk of MetS in AS patients (OR = 2.385; 95% CI = 1.019-5.582; P= 0.045). Lin et al 23 reported that hyperuricemia was strongly correlated with the development of MetS in subjects in Taiwan. The possible common mechanisms underlying the development of hyperuricemia and MetS were also identified: endothelial damage via oxidativeredox stress, systemic inflammation, adipokines (such as leptin), unhealthy diets, and lack of physical activity. 23 Additionally, studies have demonstrated that people with hyperuricemia had a higher risk of developing hypertension, overweight/obesity, type 2 diabetes mellitus, kidney diseases, and CVD. 24 Recently, Zhu et al 25 found
that without concomitant gout, significant deposition of monosodium urate crystals occurred in the sacroiliac joint of patients with axial spondyloarthropathy and exacerbated the radiographic progression of their disease. Thus, the current evidence suggests that hyperuricemia cannot be ignored in AS patients. We found that BASDAI, CRP, ESR, and disease duration were not different in the MetS and non-MetS AS patients, which was consistent with both Malesci's 10 and Maia's 13 reports, while Papadakis et al 11 found that MetS AS patients had higher BASDAI (P< 0.05) and longer disease duration (P<0.05). In addition, non-MetS AS patients in our study showed significantly higher BASFI indices than the MetS AS patients (P= 0.043), while the univariate regression analyses were not different (P= 0.137). Previous studies also showed no difference of BASFI between the two groups, 10-13 and so our results support the idea that BASFI has no bearing on MetS in AS patients.
The stepwise multivariate regression analysis in our study also suggested that high BMI independently increases the prevalence of MetS in AS patients (OR = 5.165; 95% CI = 1.935-13.787; P= 0.001). Moreover, high BMI has been reported to be a crucial determinant MetS in rheumatoid arthritis, 26 systemic lupus erythematosus, 27 and psoriasis. 28 The mechanisms for accelerating MetS by high BMI have also been explored: more proinflammatory cytokines (including TNF-α and IL-6) and adipokines (such as leptin and adiponectin) are released by fat tissue, which adversely affect MetS. 29 As the present report is the first study concerning the prevalence of MetS in mainland Chinese AS patients, some limitations should be mentioned. First, socioeconomic factors such as educational attainment, field of employment, and poverty level were not taken into account. These factors may also affect the prevalence of MetS. Second, a cross-sectional study design might not be useful to determine causality between AS and presence of MetS. Third, this was a single-center study; thus, its reliability and representativeness were open to question.
Conclusion
This study showed a greater prevalence of MetS in mainland Chinese AS patients than controls. AS patients with hyperuricemia or/and high BMI are more susceptible to MetS. Our study indicates that, beyond traditional CVD risk factors, special attention should be paid to effective control of SUA for preventing MetS in AS patients.
